Literature DB >> 2229385

Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers.

C V Hanson1, L Crawford-Miksza, H W Sheppard.   

Abstract

To perform a human immunodeficiency virus (HIV) plaque assay in nonadherent host cells, we developed a novel technique in which HIV-infected MT-2 cells were formed into monolayers by centrifugation through molten agarose. Infection, formation of cell monolayers, and enumeration of plaques all took place in 96-well microtiter plates. When this process was preceded by 18 h of incubation of HIV with patient serum samples, neutralizing antibody titers between 1:10 and 1:5,000 could be accurately determined in patient serum samples. In addition to the determination of neutralizing antibody titers (with the use of various serum dilutions and a constant virus concentration), neutralization indices could also be determined with different virus dilutions and a single dilution of patient serum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229385      PMCID: PMC268098          DOI: 10.1128/jcm.28.9.2030-2034.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Antibody to lymphadenopathy-associated virus in AIDS.

Authors:  D D Ho; T R Rota; M S Hirsch
Journal:  N Engl J Med       Date:  1985-03-07       Impact factor: 91.245

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  Neutralizing antibody and clinical status of human immunodeficiency virus (HIV)-infected individuals.

Authors:  D R Alesi; F Ajello; G Lupo; F Vitale; M Portera; F Spadaro; N Romano
Journal:  J Med Virol       Date:  1989-01       Impact factor: 2.327

4.  Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release.

Authors:  W E Robinson; D C Montefiori; D H Gillespie; W M Mitchell
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

5.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.

Authors:  R D Salter; D N Howell; P Cresswell
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

6.  Deficient LAV1 neutralising capacity of sera from patients with AIDS or related syndromes.

Authors:  F Clavel; D Klatzmann; L Montagnier
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

7.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

8.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

9.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

10.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.

Authors:  S D Smith; M Shatsky; P S Cohen; R Warnke; M P Link; B E Glader
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

View more
  8 in total

1.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Quantitative colorimetric microneutralization assay for characterization of adenoviruses.

Authors:  L K Crawford-Miksza; D P Schnurr
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

3.  In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.

Authors:  C F Barbas; D Hu; N Dunlop; L Sawyer; D Cababa; R M Hendry; P L Nara; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

4.  Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  M K Gorny; J Y Xu; V Gianakakos; S Karwowska; C Williams; H W Sheppard; C V Hanson; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

5.  Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex.

Authors:  C Y Wang; L S Sawyer; K K Murthy; X Fang; A M Walfield; J Ye; J J Wang; P D Chen; M L Li; M T Salas; M Shen; M C Gauduin; R W Boyle; R A Koup; D C Montefiori; J R Mascola; W C Koff; C V Hanson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

6.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 7.  To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1.

Authors:  Sarah A Griffith; Laura E McCoy
Journal:  Front Immunol       Date:  2021-10-19       Impact factor: 7.561

8.  Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity.

Authors:  Lokesh Agrawal; W Haq; Carl Veith Hanson; D Nageswara Rao
Journal:  J Immune Based Ther Vaccines       Date:  2003-11-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.